Access Approaches, Treatments, and Collaborations

Innovative medicines offer our best hope to effectively manage disease and contain long-term healthcare costs, which is why Amgen prices its medicines responsibly, partners with payers to align on value, and develops patient support programs to help ensure broad access of our novel therapies to appropriate patients. Our high-quality, potentially more affordable biosimilars provide additional treatment options and have the potential to expand access.1

  1. IQVIA (2018). The Impact of Biosimilar Competition in Europe. PDF file. Retrieved from: https://www.medicinesforeurope.com/wp-content/uploads/2017/05/IMS-Biosimilar-2017_V9.pdf